Aurinia Announces Positive Topline Results From the AURORA 2 Continuation Study of LUPKYNIS™ (voclosporin) for the Treatment of Adults With Active Lupus Nephritis (LN) Dec 9, 2021
Aurinia Announces Updated Interim Results from the AURORA 2 Continuation Study of LUPKYNIS (voclosporin) for the Treatment of Lupus Nephritis Nov 1, 2021
Aurinia Pharmaceuticals to Release Third Quarter 2021 Financial Results on November 3, 2021 Oct 27, 2021
Aurinia Pharmaceuticals to Present Five Abstracts at ASN Kidney Week 2021 and ACR Convergence 2021 Oct 26, 2021
Aurinia Pharmaceuticals to Participate in H.C. Wainwright 23rd Annual Global Investment Conference Sep 10, 2021
